Longitudinal plasma proteomic analysis of 1117 hospitalized patients with COVID-19 identifies features associated with severity and outcomes
Science Advances · 24.05.2024 · 10 (21)
DOI: 10.1126/sciadv.adl5762 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, erschienen am 24.05.2024. Verfasst von Arthur Viode und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Boston Children's Hospital, Boston, MA, USA. Hauptthemen laut MEDLINE: COVID-19, Proteomics, SARS-CoV-2, Hospitalization. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 102 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, NIA NIH HHS.
Abstract (Originalsprache)
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is characterized by highly heterogeneous manifestations ranging from asymptomatic cases to death for still incompletely understood reasons. As part of the IMmunoPhenotyping Assessment in a COVID-19 Cohort study, we mapped the plasma proteomes of 1117 hospitalized patients with COVID-19 from 15 hospitals across the United States. Up to six samples were collected within ~28 days of hospitalization resulting in one of the largest COVID-19 plasma proteomics cohorts with 2934 samples. Using perchloric acid to deplete the most abundant plasma proteins allowed for detecting 2910 proteins. Our findings show that increased levels of neutrophil extracellular trap and heart damage markers are associated with fatal outcomes. Our analysis also identified prognostic biomarkers for worsening severity and death. Our comprehensive longitudinal plasma proteomics study, involving 1117 participants and 2934 samples, allowed for testing the generalizability of the findings of many previous COVID-19 plasma proteomics studies using much smaller cohorts.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Boston Children's Hospital, Boston, MA, USA.
- Harvard Medical School, Boston, MA, USA.
- Precision Vaccines Program, Boston Children's Hospital, Boston, MA, USA.
- Department of Neuropsychology and Psychopharmacology, EURON, Faculty of Psychology and Neuroscience, Maastricht University, Maastricht, Netherlands.
- Broad Institute of MIT & Harvard, Cambridge, MA, USA.
- F. M. Kirby Neurobiology Center, Boston Children's Hospital, Boston, MA, USA.
ORCID-Profile: Arthur Viode, Kinga K Smolen, Patrick van Zalm, Meenakshi Jha, Kenneth Parker, Ofer Levy, Judith A Steen, Hanno Steen
Förderung
- NIAID NIH HHS
- NIA NIH HHS
Zitieren
APA
Viode, A., Smolen, K. K., van Zalm, P., Stevenson, D., Jha, M., Parker, K., IMPACC Network‡, Levy, O., Steen, J. A., & Steen, H. (2024). Longitudinal plasma proteomic analysis of 1117 hospitalized patients with COVID-19 identifies features associated with severity and outcomes. Science Advances, 10(21). https://doi.org/10.1126/sciadv.adl5762
Vancouver
Viode A, Smolen KK, van Zalm P, Stevenson D, Jha M, Parker K, et al. Longitudinal plasma proteomic analysis of 1117 hospitalized patients with COVID-19 identifies features associated with severity and outcomes. Science Advances. 2024;10(21). doi:10.1126/sciadv.adl5762
BibTeX
@article{Viode2024,
author = {Viode, Arthur and Smolen, Kinga K and van Zalm, Patrick and Stevenson, David and Jha, Meenakshi and Parker, Kenneth and IMPACC Network‡, IMPACC Network‡ and Levy, Ofer and Steen, Judith A and Steen, Hanno},
title = {Longitudinal plasma proteomic analysis of 1117 hospitalized patients with COVID-19 identifies features associated with severity and outcomes},
journal = {Science Advances},
year = {2024},
volume = {10},
number = {21},
doi = {10.1126/sciadv.adl5762}
}
EUVIMED